Not yet recruitingEarly Phase 1NCT06690359

IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients

Studying IgA Nephropathy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.
Principal Investigator
xiangmei Chen, doctorate
Chinese PLA General Hospital
Intervention
IM19 chimeric antigen receptor T cell injection(combination_product)
Enrollment
12 enrolled
Eligibility
18 years · All sexes
Timeline
2024 – 2026

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06690359 on ClinicalTrials.gov

Other trials for IgA Nephropathy

Additional recruiting or active studies for the same condition.

See all trials for IgA Nephropathy →

← Back to all trials